MedTrace Logo

Comparative Validation of "Blinq" and "2WIN" Vision Screeners

NCT04195711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-10-19

No results posted yet for this study

Summary

After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending.

Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.

Conditions

  • Strabismic Amblyopia
  • Refractive Amblyopia
  • Strabismus

Interventions

DIAGNOSTIC_TEST

objective pediatric vision screen, "blinq,"

hand-held birefringent screener for simultaneous foveation

Sponsors & Collaborators

  • Alaska Blind Child Discovery

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2019-11-26
Completion
2019-11-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04195711 on ClinicalTrials.gov